Terms: = Endocrine gland cancer AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR AND Prognosis
16 results:
1. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract] [Full Text] [Related]
2. foxo1 promotes ovarian cancer by increasing transcription and METTL14-mediated m
Tan L; Wang S; Huang S; Tie Y; Sai N; Mao Y; Zhao S; Hou Y; Dou H
Cancer Sci; 2024 Apr; 115(4):1224-1240. PubMed ID: 38403332
[TBL] [Abstract] [Full Text] [Related]
3. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
4. A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Wu M; Gu S; Xu S; Wu Y; Wang Y
J Ovarian Res; 2023 Apr; 16(1):86. PubMed ID: 37120633
[TBL] [Abstract] [Full Text] [Related]
5. foxo1 overexpression is correlated with poor prognosis in epithelial ovarian cancer.
Liu L; Yi J; Yuan J; Yao T; Lin Z; Ning Y; Zeng Z
Cancer Biomark; 2020; 28(1):1-8. PubMed ID: 32224523
[TBL] [Abstract] [Full Text] [Related]
6. Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/foxo1 pathway.
Ma L; Sun Y; Li D; Li H; Jin X; Ren D
Aging (Albany NY); 2020 Mar; 12(6):5336-5351. PubMed ID: 32202508
[TBL] [Abstract] [Full Text] [Related]
7. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
Gong G; Lin T; Yuan Y
J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
[TBL] [Abstract] [Full Text] [Related]
8. Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma.
Meng Z; Ren D; Zhang K; Zhao J; Jin X; Wu H
Aging (Albany NY); 2020 Mar; 12(6):5048-5070. PubMed ID: 32181755
[TBL] [Abstract] [Full Text] [Related]
9. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/foxo1 axis in papillary thyroid carcinoma.
Feng Z; Chen R; Huang N; Luo C
Life Sci; 2020 Mar; 244():117298. PubMed ID: 31953163
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic implications of forkhead box protein O1 (foxo1) and paired box 3 (PAX3) in epithelial ovarian cancer.
Han GH; Chay DB; Nam S; Cho H; Chung JY; Kim JH
BMC Cancer; 2019 Dec; 19(1):1202. PubMed ID: 31823759
[TBL] [Abstract] [Full Text] [Related]
11. Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.
Peng H; Deng Y; Wang L; Cheng Y; Xu Y; Liao J; Wu H
J Mol Neurosci; 2019 Nov; 69(3):399-410. PubMed ID: 31280474
[TBL] [Abstract] [Full Text] [Related]
12. foxo1-regulated lncRNA LINC01197 inhibits pancreatic adenocarcinoma cell proliferation by restraining Wnt/β-catenin signaling.
Ling J; Wang F; Liu C; Dong X; Xue Y; Jia X; Song W; Li Q
J Exp Clin Cancer Res; 2019 Apr; 38(1):179. PubMed ID: 31027497
[TBL] [Abstract] [Full Text] [Related]
13. Integrated microarray meta-analysis identifies miRNA-27a as an oncogene in ovarian cancer by inhibiting foxo1.
Wang Z; Ji G; Wu Q; Feng S; Zhao Y; Cao Z; Tao C
Life Sci; 2018 Oct; 210():263-270. PubMed ID: 30138596
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-foxo1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
[TBL] [Abstract] [Full Text] [Related]
15. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract] [Full Text] [Related]
16. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract] [Full Text] [Related]
